KIMS - Krishna Institu.
📢 Recent Corporate Announcements
Krishna Institute of Medical Sciences Limited (KIMS) has announced a scheduled interaction with institutional investor Aberdeen. The meeting is slated for March 18, 2026, and will be conducted virtually via Zoom. This disclosure is a routine compliance filing under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session.
- Virtual meeting scheduled with Aberdeen on March 18, 2026
- Interaction to be conducted via Zoom Meeting mode
- Compliance filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be disclosed
Krishna Institute of Medical Sciences Limited (KIMS) has announced its participation in a group meeting with institutional investors and analysts. The event, titled 'Chasing Growth 2026', is organized by Kotak Securities and will take place in Mumbai on February 25, 2026. This disclosure is a routine regulatory filing under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this interaction.
- Group meeting scheduled with analysts and institutional investors on February 25, 2026
- Participation in the 'Chasing Growth 2026' conference organized by Kotak Securities
- The meeting will be held in a physical format in Mumbai, India
- Company confirms that no unpublished price sensitive information will be disclosed
Krishna Institute of Medical Sciences Limited (KIMS) has announced a scheduled interaction with Lion Global Investors on February 19, 2026. The meeting is set to take place virtually via Zoom as part of an investor conference. This disclosure is a routine filing under SEBI Listing Obligations and Disclosure Requirements. The company explicitly stated that no unpublished price sensitive information will be shared during the meeting.
- Meeting with Lion Global Investors scheduled for February 19, 2026
- The interaction will be held through a virtual Zoom Meeting mode
- Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015
- Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed
KIMS reported a record-breaking quarter with total revenue crossing ₹1,003 crores, a 29.2% YoY increase driven by aggressive expansion. However, consolidated PAT declined significantly to ₹52 crores from ₹93 crores YoY, primarily due to gestation losses from seven new hospitals launched in 2025. Management expects the Thane and Bangalore units to reach EBITDA neutrality by Q1 FY27, which should trigger margin recovery. Operational metrics remain robust with ARPOB growing 20.5% YoY, supported by high-value transplant procedures in new clusters.
- Total revenue reached ₹1,003 crores, marking a 29.2% YoY growth and crossing the ₹1,000 Cr quarterly mark for the first time.
- EBITDA margins compressed to 20.4% from 25.9% YoY due to operational costs of 7 new units launched across 5 states.
- Average Revenue Per Operating Bed (ARPOB) grew by 20.5% YoY, significantly aided by 25 transplants in the new Bangalore unit.
- Consolidated PAT fell 44% YoY to ₹52 crores, resulting in a diluted EPS of ₹1.3 compared to ₹2.16 in the previous year.
- Andhra cluster volumes were temporarily impacted by a one-month strike related to the Aarogyasri scheme, though recovery was noted in January.
Krishna Institute of Medical Sciences (KIMS) has officially released the audio recording of its Q3 FY26 earnings conference call held on February 9, 2026. This filing is a mandatory disclosure under SEBI (LODR) Regulations to ensure transparency for all shareholders. The recording provides insights into the company's financial performance and management's outlook for the upcoming quarters. Interested parties can access the file through the company's investor relations portal.
- Audio recording of Q3 FY26 investor call made available on February 9, 2026.
- Disclosure compliant with SEBI Regulation 30 and 46(2).
- Recording accessible via the KIMS official website under the 'Investors' section.
Krishna Institute of Medical Sciences (KIMS) has issued a clarification regarding its Board Meeting outcome dated February 6, 2026. The update corrects the name of the statutory auditors to S.R. Batliboi & Associates LLP from a previously misstated name. Additionally, the company corrected its shareholding in a specific disclosure from 75.53% to 75.83%. These amendments are administrative in nature and do not impact the company's financial results or operational outlook.
- Statutory auditor name corrected to S.R. Batliboi & Associates LLP
- Shareholding percentage in specific disclosure revised from 75.53% to 75.83%
- Corrections relate to the Board Meeting outcome and Reg-30 disclosure filed on February 6, 2026
- All other information from the previous filing remains unchanged
KIMS released its Q3 and 9M FY26 investor presentation, highlighting a strong growth trajectory with total revenue reaching ₹3,067 crore in FY25. The hospital network expanded significantly from 12 units in 2024 to 18 units in 2025, reflecting aggressive geographic expansion across South and West India. EBITDA grew to ₹759 crore in FY25, maintaining a robust long-term CAGR of 29.7%. The company is targeting a total bed capacity of over 9,100 beds through upcoming projects in locations like Kompally and Gachibowli.
- Total revenue grew to ₹30,670 million in FY25, representing a 26.9% CAGR since 2005
- EBITDA reached ₹7,590 million in FY25 with a healthy long-term CAGR of 29.7%
- Hospital network expanded from 12 to 18 units within a single year between 2024 and 2025
- Future roadmap targets a massive capacity of 9,100+ beds across Telangana, AP, Maharashtra, and Kerala
- Strong institutional backing with DIIs and FIIs holding a combined 49.3% stake as of December 2025
KIMS reported a strong 26.9% YoY revenue growth, crossing the ₹1,000 crore quarterly milestone for the first time. However, profitability was significantly impacted by the operationalization of new units, with PAT declining 44% YoY to ₹52 crore and EBITDA margins contracting to 20.4% from 25.9%. Operational metrics remained robust as ARPOB grew by 20.5% YoY, indicating better realization per bed. The management remains optimistic as new units in Bangalore and Thane continue to ramp up clinical and non-clinical parameters.
- Total Revenue reached ₹1,003 Cr, growing 26.9% YoY and 3.9% QoQ.
- PAT declined to ₹52 Cr from ₹93 Cr in the previous year, a 44% drop.
- EBITDA margins compressed to 20.4% compared to 25.9% in Q3 FY25 due to costs from newer units.
- ARPOB (Average Revenue Per Occupied Bed) showed strong growth of 20.5% YoY.
- The group currently operates 7,100+ beds with plans to expand to 9,100+ beds.
The Board of KIMS has approved an additional investment of up to ₹100 Crores to acquire further shares in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in the subsidiary, which has shown strong financial performance with turnover growing from ₹419.44 Cr in FY23 to ₹597.00 Cr in FY25. The acquisition will be executed in one or more tranches from minority shareholders via cash consideration. This strategic move aims to consolidate ownership in a key performing asset specializing in orthopedics and high-end healthcare.
- Board approved ₹100 Crore investment to buy out minority shareholders in Sunshine Hospital.
- Sunshine Hospital turnover grew 28.6% year-on-year to ₹597.00 Cr in FY25.
- KIMS currently owns 75.53% of the subsidiary and seeks to further enhance this shareholding.
- The acquisition will be funded through cash based on independent valuation reports.
- Sunshine Hospital is a key asset for KIMS, focusing on high-growth segments like orthopedics and transplants.
The Board of KIMS has approved an additional investment of up to ₹100 Crores to acquire further shares in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in the subsidiary, which is a leading orthopedic and multi-specialty hospital in Hyderabad. Sunshine Hospital has shown strong growth, with its turnover increasing from ₹419.44 Crores in FY23 to ₹597.00 Crores in FY25. This strategic move aims to consolidate ownership in a high-performing asset through cash transactions with minority shareholders.
- Board approved ₹100 Crores for acquiring additional equity from minority shareholders in Sarvejana Healthcare.
- KIMS currently owns 75.53% of Sarvejana Healthcare (Sunshine Hospital).
- Sunshine Hospital reported a turnover of ₹597.00 Crores for FY25, up from ₹464.20 Crores in FY24.
- The acquisition will be executed in one or more tranches based on independent valuation.
- Sunshine Hospital is a key asset specializing in orthopedics, cardiology, and transplants.
The Board of KIMS has approved an additional investment of up to ₹100 Crores to acquire further shares from minority shareholders in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in the subsidiary, which is a leading orthopedic-focused hospital in Hyderabad. The subsidiary has shown robust growth, with turnover increasing from ₹419.44 Crores in FY23 to ₹597.00 Crores in FY25. This strategic move aims to consolidate ownership in a high-performing asset through cash-based transactions in multiple tranches.
- Approved ₹100 Crore limit for acquiring additional equity from minority shareholders in Sarvejana Healthcare.
- Current stake in the subsidiary stands at 75.53%, with the acquisition intended to further enhance control.
- Sunshine Hospital reported a significant turnover growth to ₹597.00 Crores in FY25 from ₹464.20 Crores in FY24.
- The acquisition will be completed in one or more tranches based on independent valuation.
- Sunshine Hospital is a key revenue driver specializing in orthopedics, cardiology, and transplants.
Krishna Institute of Medical Sciences Limited (KIMS) has announced its participation in the Axis Capital Flagship India Conference scheduled for February 10, 2026. The event will be held in Mumbai as a group meeting with various analysts and institutional investors. This disclosure is a routine compliance under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these interactions.
- Meeting scheduled for February 10, 2026, at the Axis Capital Flagship India Conference in Mumbai.
- The interaction is categorized as a group meeting with institutional investors and analysts.
- Formal disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Company confirmed that no unpublished price sensitive information (UPSI) will be discussed.
Krishna Institute of Medical Sciences (KIMS) has issued a revised intimation for its investor conference call, now scheduled for February 9, 2026, at 9:30 AM IST. The call, hosted by IIFL Capital, will follow the announcement of the company's Q3 FY26 financial results. Senior management, including the MD, CEO, and CFO, will participate to discuss the company's business strategy and future outlook. This is a standard procedure for listed companies to engage with the analyst community post-earnings.
- Conference call rescheduled to Monday, February 9, 2026, at 09:30 a.m. IST.
- The call aims to discuss Q3 FY26 financial performance and future business strategy.
- Key management participants include Founder & MD Dr. Bhaskara Rao Bollineni and CEO Dr. Abhinay Bollineni.
- The session is being hosted by IIFL Capital Services Limited with universal access numbers provided for India and international callers.
Krishna Institute of Medical Sciences (KIMS) has successfully passed a resolution via postal ballot to approve a material related party transaction with its subsidiary, KIMS Hospital Bengaluru Private Limited. The resolution received 93.18% support from the total votes polled, ensuring the company can proceed with its internal financial and operational arrangements. While promoters and non-institutional public shareholders showed near-unanimous support, approximately 12.75% of institutional votes were cast against the proposal. This approval is a necessary step for the company's integrated operations and expansion in the Bengaluru region.
- Resolution for Material Related Party Transaction with KIMS Hospital Bengaluru Private Limited passed with 93.18% majority.
- Total of 31.85 crore votes were polled, representing a 79.61% turnout of the total shareholding.
- Public institutional investors cast 2.17 crore votes (12.75% of their category) against the resolution.
- Promoter group and non-institutional public shareholders voted nearly 100% in favor of the transaction.
- The resolution is deemed passed as of February 01, 2026, the final date of e-voting.
Krishna Institute of Medical Sciences (KIMS) has scheduled an earnings conference call for Saturday, February 7, 2026, at 10:30 AM IST. The call is intended to discuss the company's financial performance for the third quarter of FY26 along with its future business strategy and outlook. Key management personnel, including the Founder & MD, Executive Director & CEO, and the CFO, will be present to address investor queries. The event is being hosted by IIFL Capital Services Limited.
- Conference call scheduled for February 7, 2026, following Q3FY26 results.
- Management participants include Dr. Bhaskara Rao Bollineni (MD) and Dr. Abhinay Bollineni (CEO).
- Discussion will focus on Q3FY26 financial results and future business strategy.
- Universal access dial-in numbers provided are +91 22 6280 1259 and +91 22 7115 8160.
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 21% YoY to INR 3,039 Cr in FY25 from INR 2,503 Cr in FY24. Growth was driven by a 22% CAGR between FY20-24, supported by bed additions and improved ARPOBD. The flagship Secunderabad hospital's revenue contribution has been successfully diluted from 60% in FY18 to <35% in FY25.
Geographic Revenue Split
Telangana and Andhra Pradesh remain the core markets with 15 hospitals. Expansion is underway in Maharashtra (Nashik, Mumbai, Nagpur), Karnataka (Bengaluru), and Kerala. The Secunderabad flagship now accounts for <35% of revenue, down from 60% in FY18, indicating improved geographic diversification.
Profitability Margins
PAT margin stood at 13.6% in FY25 (INR 415 Cr) compared to 13.4% in FY24 (INR 336 Cr). Operating margins improved by 30 bps to 26.3% in FY25 from 26% in FY24. RoCE moderated to 16.5% in FY25 from 18.1% in FY24 due to aggressive front-ended capex but is expected to stabilize between 12-15%.
EBITDA Margin
Operating profitability is maintained at 25-26% as of FY25. While new greenfield hospitals in Nashik and Bengaluru may cause a temporary drag, the company expects to sustain margins above 25% due to high operational efficiency and quick turnaround of acquired assets.
Capital Expenditure
KIMS incurred INR 1,792 Cr capex in FY25 for greenfield projects in Thane and Bengaluru. Planned capex of INR 2,200-2,500 Cr is scheduled between FY26 and FY28 to add 2,000 beds and establish oncology departments.
Credit Rating & Borrowing
Long-term rating upgraded to CRISIL AA/Stable from CRISIL AA-/Positive in April 2024; short-term rating reaffirmed at CRISIL A1+. Interest coverage ratio moderated to 8.24x in FY25 from 11.99x in FY24 due to increased debt servicing requirements.
Operational Drivers
Raw Materials
Medical consumables, surgical implants, and pharmaceuticals represent the primary operational costs, though specific percentage of total cost is not disclosed in available documents.
Capacity Expansion
Current capacity is 3,975 beds as of Dec 2023. KIMS added 1,000 beds in FY25 (including 325 beds in Nashik). Planned expansion includes 1,100 beds in FY26 and another 1,000 beds across FY27-28, with a long-term target of 3,000 beds in Kerala via the O&M model.
Raw Material Costs
Not disclosed as a specific percentage of revenue; however, operating efficiencies are driven by a 3.66-day Average Length of Stay (ALOS) in FY25, down from 4.11 days in FY24, which optimizes consumable usage per patient.
Manufacturing Efficiency
Operational efficiency is reflected in high ARPOBD and 'good' occupancy levels. The group achieved a 30 bps improvement in operating margin to 26.3% in FY25 through better performance at Begumpet and Nagpur facilities.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be achieved through a mix of greenfield expansions (Bengaluru hospitals starting in 3-4 months), brownfield additions (2,000 beds by FY28), and an asset-light O&M model in Kerala targeting 3,000 beds. The strategy focuses on reducing flagship dependence and expanding into high-ARPOB markets like Mumbai and Bengaluru.
Products & Services
Tertiary and quaternary healthcare services including cardiology, oncology, neurology, and multi-specialty surgical procedures.
Brand Portfolio
KIMS Hospitals, Sunshine Hospitals (Sarvejana Healthcare).
New Products/Services
Expansion into specialized Oncology departments across the hospital network is a key focus for the FY26-28 capex cycle.
Market Expansion
Entry into Bengaluru (2 hospitals in 3-4 months), Thane, and Kerala (O&M model) to diversify beyond the core Telangana/AP cluster.
Market Share & Ranking
One of the leading tertiary care players in Andhra Pradesh and Telangana; Secunderabad facility is one of the largest single-location hospitals in India with ~1,000 beds.
Strategic Alliances
General Atlantic holds a 42.6% minority stake. KIMS also uses an O&M (Operations and Management) model for expansion in Kerala to receive management fees without heavy capital outlay.
External Factors
Industry Trends
The hospital industry is seeing a shift toward regional consolidation and 'hub-and-spoke' models. KIMS is positioning itself by expanding from its Hyderabad hub into adjacent states while maintaining a high-margin tertiary care focus.
Competitive Landscape
Competes with other major multi-specialty chains in South and West India; competitive edge maintained through lower capital cost per bed and efficient turnaround of acquired assets.
Competitive Moat
The primary moat is the 'Doctor-Partnership' model which creates high switching costs for top surgeons and ensures stable clinical outcomes. This is sustainable as it aligns physician incentives with hospital profitability.
Macro Economic Sensitivity
Sensitive to healthcare spending trends and government reimbursement rates for institutional payers (CGHS/ECHS).
Consumer Behavior
Increasing preference for insurance-backed private healthcare over government facilities, with insurance and institutional payers now making up 70% of the KIMS payer mix.
Geopolitical Risks
Minimal direct impact, though global supply chains for high-end medical machinery (MRI, CT scanners) could be affected by trade barriers.
Regulatory & Governance
Industry Regulations
Subject to National Pharmaceutical Pricing Authority (NPPA) caps on medical devices/implants and state-level clinical establishment acts. Compliance with empanelment criteria for government schemes (CGHS/ECHS) is critical for volume.
Risk Analysis
Key Uncertainties
The primary risk is the successful ramp-up of 2,000 new beds. Failure to achieve optimal occupancy could lead to Debt/EBITDA exceeding the projected 3.5x in FY26, potentially impacting credit metrics.
Geographic Concentration Risk
While reducing, the company still has significant concentration in Telangana and Andhra Pradesh, making it vulnerable to regional regulatory changes or local competition.
Third Party Dependencies
High dependency on key doctors; however, this is mitigated by the equity-sharing model.
Technology Obsolescence Risk
Medical technology requires constant reinvestment; KIMS is addressing this through its INR 2,200-2,500 Cr capex plan which includes new oncology equipment.
Credit & Counterparty Risk
40% of revenue comes from government/institutional payers (CGHS/ECHS), which typically have longer receivable cycles compared to cash/insurance patients.